Anika Therapeutics

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Anika Therapeutics reports strong Q4 earnings, eyes growth opportunities

Anika Therapeutics delivered strong financial performance in Q4 2022, with revenue growth and strategic investments driving growth targets for 2023. The company is focused on product launches, expanding its portfolio, and preparing for the launch of the RevoMotion Reverse Shoulder System.
While facing challenges such as higher stock-based compensation and lower EBITDA expected in 2023, Anika remains optimistic about the value inflection point in 2023. The company's emphasis on growth initiatives and commercial optimization positions it for future opportunities.

Anika Therapeutics reports growth in core segments and strategic investments

Anika Therapeutics showed positive revenue growth in Q1, driven by core business segments.
Despite a net loss, Anika is strategically positioning itself as a global leader in joint preservation.
Investments in new products and regulatory progress with Cingal indicate a focus on innovation and expansion.
Maintaining strong gross margins amidst increased operating expenses highlights operational efficiency.

Anika Therapeutics posts robust Q2 results, eyes growth opportunities

Anika Therapeutics reported strong Q2 results, raising its revenue outlook for 2023.
Despite international challenges, the company sees opportunities for growth in key segments.
Progress in FDA approvals, partnerships, and new product launches position Anika for future success.
Maintaining a focus on innovation and market expansion will be crucial for sustained growth.

Anika Therapeutics raises guidance on strong Q3 performance and outlook

Anika Therapeutics showcased robust growth in key segments, leading to an optimistic outlook for the year. Despite challenges in restructuring sales operations, the company is well-positioned for continued success with a focus on profitability and new product launches.

Anika Therapeutics exceeds Q4 expectations, eyes Hyalofast's U.S. potential

Anika Therapeutics delivered robust financial performance, focusing on driving new products for growth and operational efficiency. The company aims to accelerate profitability targets and is on track with product launches, making strategic adjustments based on feedback.

Anika Therapeutics reports Q1 revenue growth and strategic product advancements

Anika Therapeutics demonstrated solid financial performance in Q1 2024, driven by revenue growth, cost reduction initiatives, and positive market feedback on key products.
While facing challenges such as FDA approval requirements and leadership transition, the company's strengths in product portfolio and distribution agreements position it well for future growth.
Opportunities in FDA designations, revenue growth expectations, and operational improvements present avenues for Anika to enhance market presence and financial performance in the coming quarters.

Anika Therapeutics reports Q3 revenue, focuses on core products

Anika Therapeutics faces challenges with workforce reduction and financial losses
However, strategic focus on core HA products and revenue reclassification show promise
Opportunities lie in revenue growth in the commercial channel and long-term investments
Overall, Anika Therapeutics aims for sustainable growth and value creation

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company's main focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and its products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.

Tactoset cleared by the FDA to be combined with autologous bone marrow aspirate, a core element for regenerative healing

Anika Continues to Expand Addressable Market for Tactoset® Injectable Bone Substitute with Additional 510(k) Clearance from FDA

BEDFORD, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global joint preservation company in early intervention orthopedics, today announced that it has filed its preliminary proxy materials with the Securities and Exchange Commission (“SEC”) in connection with its upcoming 2023 Annual Meeting of Stockholders (the “Annual Meeting”). The meeting date has not yet been scheduled and shareholders do not need to take any action at this time.

Anika Files Preliminary Proxy Statement

Recently Commenced Full Market Release of X-Twist™ Fixation System, a Cornerstone Product in Anika's Sports Medicine Portfolio

Anika Highlights Products in High Growth Segments of Joint Preservation during the 2023 AAOS Annual Meeting

Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q4 2022 Earnings Conference Call March 6, 2023 5:00 PM ET Company Participants Mark Namaroff - VP, IR, ESG and Corporate Communications Cheryl Blanchard - President & CEO Mike Levitz - EVP & CFO Conference Call Participants George Sellers - Stephens Jim Sidoti - Sidoti & Company Mike Petusky - Barrington Research Operator Greetings, and welcome to Anika's Fourth Quarter and Year-End 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Anika Therapeutics, Inc. (ANIK) Q4 2022 Earnings Call Transcript

Anika (ANIK) delivered earnings and revenue surprises of -54.55% and 3.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Anika Therapeutics (ANIK) Reports Q4 Loss, Tops Revenue Estimates

Delivered Fourth Quarter Revenue Growth of 11% and Full Year 2022 Revenue Growth of 6%

Anika Reports Fourth Quarter and Year-End Fiscal 2022 Financial Results

BEDFORD, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate at the Canaccord Genuity Musculoskeletal Conference in Las Vegas, NV on Tuesday, March 7, 2023 at 3:00 p.m. PT (6:00 p.m. ET).

Anika to Participate in the Canaccord Genuity Musculoskeletal Conference

BEDFORD, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its fourth quarter and year-end 2022 financial results after the close of the market on Monday, March 6, 2023 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Anika to Issue Fourth Quarter and Year-End 2022 Financial Results on Monday, March 6, 2023

BEDFORD, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today issued the following statement in response to the letter by Caligan Partners LP:

Anika Issues Statement

Believes Current Board's Strategic Missteps and Poor Capital Allocation Has Led to Significant Underperformance Offers Three Actions for Significant Change, Including Strategic Review NEW YORK , Feb. 21, 2023 /PRNewswire/ -- Caligan Partners LP ("Caligan"), one of the largest shareholders of Anika Therapeutics, Inc. (NASDAQ: ANIK) ("Anika" or the "Company"), today issued an open letter to the board of directors of Anika in connection with Anika's poor share performance, caused by the heavy losses it is incurring in its joint preservation segment, and its failure to maximize the value of Anika's viscosupplement portfolio. The full text of the letter is in the attached PDF.

Caligan Partners Issues Open Letter to Anika Board

RevoMotion significantly expands Anika's shoulder arthroplasty portfolio and provides a new solution in the over $800 million U.S. reverse shoulder market

Anika Announces First Surgeries Performed Using the New RevoMotion™ Reverse Shoulder Arthroplasty System and Commences Limited Market Release in the United States

Here is how Anika Therapeutics (ANIK) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.

Is Anika Therapeutics (ANIK) Stock Outpacing Its Medical Peers This Year?

BHP Billiton

Crown Crafts

REX American Resources

Schneider National

STMicroelectronics NV ADR RegS

Universal Forest Products

With Americans being an optimistic bunch, the general assumption that the equities sector will rise following the ugly year in 2022 fundamentally bolsters several stocks to buy. However, it's important to be selective.

7 Stocks to Buy Before the Market Starts to Soar in 2023

Anika (ANIK) delivered earnings and revenue surprises of -20.83% and 10.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Anika Therapeutics (ANIK) Reports Q3 Loss, Tops Revenue Estimates

Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q3 2022 Results Conference Call November 8, 2022 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations, ESG and Corporate Communications Dr. Cheryl Blanchard - President and Chief Executive Officer Mike Levitz - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants George Sellers - Stephens Incorporated Mike Petusky - Barrington Research Jim Sidoti - Sidoti & Company Operator Good evening, ladies and gentlemen, and welcome to Anika's Third Quarter 2022 Earnings Conference Call. Today's conference is being recorded.

Anika Therapeutics, Inc. (ANIK) Q3 2022 Earnings Call Transcript

Anika Reports Third Quarter Fiscal 2022 Financial Results

Study Demonstrated Superiority of Cingal, a Single-Injection Hyaluronic Acid-Based Viscosupplement Combined with Fast-Acting Steroid, Over Steroid Alone, for Osteoarthritis Pain Relief at 26 Weeks

Anika's Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study

BEDFORD, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2022 financial results after the close of the market on Tuesday, November 8, 2022 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Anika to Issue Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

X-Twist expands Anika's sports medicine portfolio with a cornerstone suture anchor system ideal for key repairs in the shoulder, foot and ankle, and other extremities X-Twist expands Anika's sports medicine portfolio with a cornerstone suture anchor system ideal for key repairs in the shoulder, foot and ankle, and other extremities

Anika Announces First Surgeries Performed Using the X-Twist™ Fixation System and Commences Limited Market Release

Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations, ESG and Corporate Communications Cheryl Blanchard - President and Chief Executive Officer Michael Levitz - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants James Sidoti - Sidoti & Company Michael Petusky - Barrington Research Operator Good evening, ladies and gentlemen, and welcome to Anika's Second Quarter 2022 Earnings Conference Call. [Operator Instructions] I will now turn the call over to Mark Namaroff, Vice President of Investor Relations, ESG and Corporate Communications.

Anika Therapeutics Inc. (ANIK) CEO Cheryl Blanchard on Q2 2022 Results - Earnings Call Transcript

Second quarter revenue growth up 4% X-Twist ™ 510(k) clearance received; Limited market release on schedule for 2H 2022

Anika Reports Second Quarter Fiscal 2022 Financial Results

BEDFORD, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received the Accelerating the Cutting Edge (ACE) Award from the American Orthopaedic Society for Sports Medicine (AOSSM) for Tactoset® Injectable Bone Substitute for hardware augmentation. This award highlights the innovative nature of Tactoset, a calcium phosphate based, biocompatible bone graft substitute that incorporates Anika's core hyaluronic acid (HA) technology, and its use to augment hardware and support bone fragments during surgical procedures. The HA component of Tactoset makes the product highly flowable, easily injectable and able to interdigitate trabecular bone architecture, such as insufficiency fractures, with overall improved handling characteristics compared to competitive products.

Anika Receives the ACE Award for Cutting-Edge Innovation for Tactoset® Injectable Bone Substitute from the American Orthopedic Society for Sports Medicine

BEDFORD, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2022 financial results after the close of the market on Wednesday, August 3, 2022 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Anika to Issue Second Quarter 2022 Financial Results on Wednesday, August 3, 2022

X-Twist provides a simple, versatile knotless suture anchor system ideal for key repairs in the shoulder, foot and ankle, and other extremities X-Twist provides a simple, versatile knotless suture anchor system ideal for key repairs in the shoulder, foot and ankle, and other extremities

Anika Receives FDA 510(k) Clearance for the X-Twist™ Knotless Fixation System, Expanding its Sports Medicine Soft Tissue Portfolio

BEDFORD, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the UBS Global Healthcare Conference 2022 being held in-person at the Lotte New York Palace, New York, NY, on Wednesday, May 25, 2022. Anika will host a live presentation with fireside chat starting at 11:30am ET. Management will also be participating in 1x1 investor meetings on the same day.

News for Anika Therapeutics Stock (ANIK)